Description
.
Vendredi 3 avril à 14h30 / Friday 3 April at 2.30 p.m
Amphi 7 (5e rouge)
Introduction : vidéo remise de prix par la Fondation Vaincre Alzheimer
Charline Chalbot
Equipe 3 / Team 3
DEVELOPMENT OF VECTORIZED RNA-BASED NANOMEDICINES AS NOVEL THERAPY FOR ALZHEIMER’S DISEASE
RNA-based therapeutics, such as small interfering RNA (siRNA), are emerging as powerful therapeutic strategy for Alzheimer’s Disease. However, to bypass the blood brain barrier (BBB), these RNA-based medicines are administered to patients via intrathecal injection (IT), which is an invasive surgical procedure that requires dedicated personnel, local anesthesia and lumbar puncture.
In her talk Charline Chalbot, Neuroscientist and PhD candidate (ED659) in the Vect2Brain team (Team 3 of the INP), will present her work on implementing vectorized-siRNA conjugates as a novel therapeutic strategy to modulate the expression of gene risk factors involved in Alzheimer’s (e.g., BACE1, QPCT). She will describe the entire pipeline from large-scale production of brain vectors to their conjugation to siRNA via click chemistry reaction, and the subsequent validation of their effects in vitro and in vivo. This work introduces a promising therapeutic strategy for silencing genes associated with neurodegeneration, including AD, offering potential for more efficient and at the same time less invasive treatments (i.e., systemic administration vs IT).
